We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

After hours: February 7 at 7:58:40 p.m. EST ...